Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

by

CTech 24/7

More stories in CTech

Anchiano

2 stories about Anchiano

Anchiano Therapeutics Schedules TASE Delisting
14.03.19|Lilach BaumerBased in Jerusalem and Cambridge, Massachusetts, clinical-stage Anchiano develops gene therapies for cancer, with a special focus on bladder cancer
Cancer Treatment Company Anchiano Therapeutics Wants to List on Nasdaq
09.01.19|Lilach BaumerThe company formerly known as BioCanCell submitted a prospectus to the SEC on Monday, with Oppenheimer & Co. as the sole underwriter

About CTech Terms of Use Privacy Policy

Back to Top